Norflurazepam Blister – 10x 10mg
€ 20,90 – € 198,75Price range: € 20,90 through € 198,75
Norflurazepam Blister 10x 10mg is described as a blister-packed research product containing N-desalkylflurazepam, a 1,4-benzodiazepine and active metabolite of flurazepam.
The supplied presentation consists of ten tablets per blister, with a nominal label claim of 10 mg norflurazepam per tablet.
The reported CAS number is 2886-65-9, pending verification.
The supplied molecular formula and molecular weight are inconsistent and must be reconciled against the intended chemical structure before publication.
The source claims ingredient purity of at least 98%, analytical identity testing, independent quality verification, and tablet content-uniformity assessment. No batch-specific documentation was supplied to substantiate these claims.
Tablet excipients, actual ingredient content, salt form, impurity profile, and storage stability have not been independently confirmed.
Norflurazepam is associated with clinically significant benzodiazepine-related hazards, including sedation, dependence, and respiratory depression, particularly in combination with other central nervous system depressants.
For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.
Norflurazepam Blister 10x 10mg – Research Material Information
Norflurazepam Blister 10x 10mg – Product Overview
Norflurazepam Blister 10x 10mg is the supplied catalog designation for blister-packed tablets described as containing N-desalkylflurazepam.
The source specifies ten units per blister with a nominal 10 mg ingredient content per unit.
This is a label claim, not a verified finished-tablet assay.
No actual Certificate of Analysis, tablet-content report, or batch-specific documentation was supplied.
The material is not established as a certified reference standard or approved pharmaceutical product.
Chemical Identity & Classification
Norflurazepam, also called N-desalkylflurazepam, is a 1,4-benzodiazepine compound associated with the metabolism of flurazepam.
The source reports CAS number 2886-65-9.
It also provides molecular formula C15H10ClFN3O and molecular weight 287.72 g/mol.
These specifications are inconsistent.
The supplied formula calculates to approximately 302.69 g/mol. The commonly described neutral N-desalkylflurazepam structure instead corresponds to C15H10ClFN2O, approximately 288.71 g/mol.
The intended structure, chemical form, and CAS assignment require verification.
Public chemical reference information is available through PubChem, but any reference must be matched to the exact compound rather than assumed from the product name.
Chemical & Physical Characteristics
The source describes compressed tablets enclosed in blister packaging.
No actual tablet appearance, dimension, hardness, disintegration, or formulation record was supplied.
The identities and quantities of excipients remain unknown.
The source refers to dissolution performance and storage stability, but no validated finished-product data were provided.
Blister packaging alone does not demonstrate protection against every environmental degradation mechanism.
Purity & Analytical Verification
The source claims at least 98% ingredient purity by HPLC.
It also refers to HPLC, LC-MS/MS, and NMR identity testing.
No chromatogram, spectrum, independent laboratory report, or batch-specific Certificate of Analysis was supplied.
Ingredient purity does not establish finished-tablet content.
The nominal 10 mg label claim requires separate supporting evidence from any ingredient-purity measurement.
No certified reference-material documentation, assigned reference value, or measurement-uncertainty record was supplied.
Quality Control & Batch Integrity
The source describes batch traceability, third-party testing, content-uniformity assessment, and tablet-potency variation within approximately ±3% RSD.
These claims remain unverified.
No finished-tablet assay, content-uniformity dataset, manufacturing record, or independent testing report was supplied.
Total tablet weight, ingredient purity, and actual norflurazepam content are distinct characteristics.
Claims of consistent quantitative performance should not be made without appropriate finished-product records.
Safety, Handling & Laboratory Precautions
Norflurazepam is a pharmacologically active benzodiazepine associated with central nervous system depression.
Potential hazards include marked sedation, impaired coordination, dependence, withdrawal complications, and respiratory depression.
Combining benzodiazepines with opioids, alcohol, or other central nervous system depressants can substantially increase the risk of severe harm.
The supplied source does not include a verified product-specific Safety Data Sheet.
Institutional chemical-safety procedures should address restricted access, accidental exposure, secure storage, contamination prevention, and waste disposal.
The blister presentation must not be interpreted as evidence of suitability for human administration.
Packaging, Labeling & Storage
The source describes one blister containing ten tablets, each nominally labeled as containing 10 mg norflurazepam.
The total nominal labeled ingredient quantity is therefore 100 mg per blister.
This arithmetic total is not a verified analytical measurement.
The source recommends cool, dry storage, with a suggested temperature range of 2–8°C.
No validated stability study or packaging-performance record was supplied to establish the suggested conditions as confirmed requirements.
Inventory records should distinguish the nominal content claim from verified batch information.
Intended Research Use & Market Positioning
The supplied description places the product within laboratory contexts involving benzodiazepine chemical identity and analytical documentation.
No validated calibration performance or certified reference-material status was demonstrated.
The catalog references supplied for this product are:
These listings describe different nominal strengths or packaging formats. Their analytical equivalence, formulation consistency, and actual ingredient content have not been established.
Ordering, Availability & Fulfillment
The source claims worldwide shipping, tracking, customs documentation, and IATA/DOT-compliant transport.
No current inventory information, shipment authorization, dangerous-goods classification, or carrier documentation was supplied.
These statements should not be presented as verified availability or universal shipping compliance.
Norflurazepam may be controlled or otherwise restricted under applicable national and international laws.
Research-only labeling does not establish an exemption from legal requirements.
Legal & Regulatory Disclaimer
For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.
Norflurazepam is a benzodiazepine compound whose acquisition, possession, transportation, importation, exportation, and laboratory investigation may be regulated.
Institutions remain responsible for applicable legal requirements, authorization, secure custody, and laboratory safety.
No therapeutic approval, consumer-use authorization, or certified analytical status is implied.
| Quantity |
2 ,5 ,10 ,25 |
|---|
You must be logged in to post a review.

Reviews
There are no reviews yet.